Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials

syn53181385

Created By NF Service nf-osi-service

dataType:
grantDOI: https://doi.org/10.48105/CTF.CTF-2023-10-003.pc.gr.175365
keywords:
studyName: Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials
dataStatus: Data Pending
initiative: Clinical Research Award
studyLeads: Vanessa Merker
studyStatus: Active
diseaseFocus: Neurofibromatosis type 2
grantEndDate: 1759190400000
institutions: Massachusetts General Hospital
clinicalTrial:
fundingAgency: CTF
manifestation: Quality of Life
embargoEndDate: 1790726400000
grantStartDate: 1696118400000
relatedStudies:
studyFileviewId: syn53181393
alternateDataRepository:
syn53181386
syn53181387
syn53181393
syn53181388
syn73833453
syn73833454
syn73833455

Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials page is loading…